However, its ability to prevent or delay the development of nitrate tolerance in patients with angina pectoris has not been established. Methods and Results. Ten patients with stable angina pectoris were treated with intravenous isosorbide dinitrate (ISDN; 5 mg/hr) combined with NAC (2 g i.v. over 15 minutes followed by 5 mg/kg/hr) or matching placebo for 30 hours in a double-blind, randomized, crossover study with a washout interval of 8 days. Bicycle exercise tests were performed before and at 1½2, 8, 20, 24 , and 30 hours after start of treatment. After 24 hours of infusion, exercise parameters were not significantly different from pretreatment values (p>0.05) during ISDN plus placebo, indicating development of tolerance to ISDN. In contrast, time to onset of angina, time to 1-mm ST segment depression, and total amount of ST segment depression were still significantly improved after 24-hour infusion of ISDN plus NAC (p<0.05). In addition, compared with placebo, a significant difference (p<0.05) in favor of NAC was observed regarding time to angina (507+±63 versus 445±69 seconds, mean±SEM), time to 1-mm ST segment depression (435+±43 versus 407+±45 seconds), and total ST segment depression (1.8+0.9 versus 3.1±0.4 mm).
Conclusions. These results suggest that infusion of high doses of NAC in combination with ISDN for 30 hours affects and partially prevents the development of tolerance to Exercise tests were performed with a bicycle ergometer, beginning at a 25-W load with the work load progressively increased by 25 W every second minute to a symptom-limited end point consisting of anginal pain that would stop daily life activities (total exercise time). Systolic blood pressure was recorded before exercise; at the end of each work load; and 1, 2, 4, and 10 minutes after exercise. A six-precordial-lead ECG was recorded continuously for measurement of heart rate and surveillance of ST segment changes. The amount of exercise-induced ST segment depression was used as the major objective parameter in determining exercise-induced myocardial ischemia. However, also analyzed from the exercise test were the variables of total exercise time, time to onset of angina, time to 1-mm ST depression, and the product of heart rate and systolic blood pressure (rate/pressure product) at maximal work loads. Time to 1-mm ST depression was studied in the lead that produced the largest depression during baseline exercise testing. This lead was used for comparison during the study. Total ST segment depression was calculated as the cumulative amount of ST depression in the six precordial leads at maximal comparable, intraindividually identical work loads.
Statistics
Results were analyzed using analysis of variance (ANOVA) to take into account three factors: treatment, infusion time, and treatment sequence. Comparison of variables on each study day was performed by one-way ANOVA. At each time point, differences between NAC and placebo were assessed by means of paired Student's t tests. Within each study period, changes between baseline values and values recorded 1½/2 and 24 hours after the start of infusion were considered relevant and useful for comparisons. Interpretation of differences between baseline values and values recorded at other time points (8, 20 , and 30 hours) is difficult due to the influence of circadian variation on ischemic threshold and usual antianginal therapy (given several times a day). The intraindividual changes in each infusion period were calculated by subtracting the baseline from that obtained during infusion. One patient did not develop angina during treatment with ISDN plus or without NAC and was assigned the total exercise time in the statistical analysis regarding this parameter. Values are expressed as mean+SEM and 95% confidence intervals. For all analyses, a two-tailedp value of less than 
Results
Ten patients were entered into the protocol; two subjects were withdrawn from the study. One patient experienced accelerated angina pectoris during infusion of ISDN (plus placebo), and one patient developed unstable angina pectoris in the interval between the two study periods. Headache was experienced in seven of the eight ISDN-plus-NAC infusion periods and in six of the eight ISDN-plus-placebo periods. In no case was it necessary to discontinue treatment because of this undesired effect.
Results are presented for the eight patients who completed the entire study. Preinfusion (baseline) hemodynamic data and exercise results were comparable on the two study days and did not differ significantly (Tables 1 and 2 ). No carryover effect was observed.
Resting Hemodynamics
The changes in hemodynamic values over the 30-hour study periods are shown in Table 1 . Supine systolic blood pressure was acutely lowered during both infusion regimens and remained significantly decreased compared with baseline values throughout the study periods without any significant treatment difference. An increase in supine heart rate and a decrease in supine diastolic blood pressure during infusions did not reach statistical significance. With patients in the upright position, these changes were augmented; heart rate was significantly increased, and systolic and diastolic blood pressures were significantly reduced compared with pretreatment values. The changes were maintained throughout the 30-hour infusions and were not affected by NAC administration. Table 2 shows the results regarding exercise end points. Time to 1-mm ST segment depression and time to onset of angina were prolonged and significantly different after 8, 24, and 30 hours of infusion of ISDN plus NAC when compared with ISDN plus placebo ( Table 2) . Furthermore, the total amount of ST segment depression was reduced and significantly different from that of ISDN plus placebo after 20, 24, and 30 hours of treatment with ISDN plus NAC ( Table 2) .
Exercise Tolerance
Compared with baseline values, increases in time to 1-mm ST segment depression and time to angina were observed only after 1/2 hours during infusion of ISDN plus placebo, whereas a significant increase was still present after 24 hours of infusion with ISDN plus NAC (Table 2 and Figures 1, 2, and 4) . Compared with baseline, ST segment depression was reduced after 11/2 hours during both infusion periods (Figures 1 and 2 ). Total exercise time was increased after 1.5 hours but was not statistically different from baseline values after 24 (Table 2) . At peak exercise, alterations in the rate/pressure product were not statistically significant. There was no indication of a treatment difference regarding maximal heart rate and systolic blood pressure (Table 1) .
Discussion
Time to onset of angina (sec) Several studies have shown that the magnitude and duration of the circulatory and antianginal effects of organic nitrates are reduced during sustained therapy.1,2,5,7 In the present study, an initial improvement in exercise parameters after 11/2 hours of ISDN plus placebo infusion gradually declined; at high steadystate plasma nitrate concentrations (data not shown), exercise parameters after 24 hours were similar to preinfusion values. Veins rather than arteries may be the primary site of tolerance development,19-21 and as previously described by Zimrin et al,5 tolerance to the antianginal effects developed, although the nitrate effect on systemic blood pressure was still present. This is also in accordance with other findings showing that tolerance on right atrial pressure and pulmonary vascular resistance may develop more rapidly than tolerance on systemic vascular resistance and cardiac index. 22 Organic nitrates interact with thiols to generate labile vasoactive S-nitrosothiols and nitric oxide, which activates guanylate cyclase and causes smooth muscle relaxation.8,9 Because thiols are required for the metabolism of organic nitrates, the mechanism of tolerance development has been attributed to a depletion of sulfhydryl groups caused by prolonged exposure to nitrates.9,10,23,24 In line with this hypothesis, administration of the sulfhydryl donor NAC has produced reversal of tolerance in some in vitro15, 23 Assuming continued availability of the sulfhydryl donor throughout the study period, the present data therefore also support an obligatory role for mechanisms for tolerance development other than sulfhydryl depletion. This is consistent with data suggesting that multiple mechanisms (e.g., tolerance to S-nitrosothiols, neurohormonal activation, and plasma volume expansion) interact and may contribute to the development of tolerance. 6"12,3' In the present study, we used a high dose of NAC. It is not known whether lower intravenous doses of NAC are similarly effective. However, in the general management of chronic stable angina, the use of smaller oral doses would be necessary because a high frequency of gastrointestinal side effects occurs with chronic administration.32 In a recent study with oral ISDN and NAC (600 mg q.i.d.), we found a small beneficial effect of NAC on ST segment depression during ISDN therapy, although the changes were less pronounced than in the present study.33 It may therefore be possible that NAC is effective in the prevention of tolerance in relatively low doses compared with the high doses needed in the reversal of tolerance. Finally, NAC has free radical-scavenging properties34 and may potentiate the effect of nitrates on platelet aggregation.35 At present, however, additional studies are required to delineate the potential benefits of an interaction between different organic nitrates and different types and doses of sulfhydryl donor substances in the management of ischemic heart disease.
In conclusion, the present study represents the first reported clinical investigation into the prevention of nitrate tolerance by high intravenous doses of NAC in patients with angina pectoris. The results suggest that an infusion of NAC in combination with ISDN for 30 hours affects and partially prevents the development of tolerance to the antianginal effects normally seen during infusion with ISDN.
